Synthetic biomarkers for differential serological diagnosis of Cutaneous Leishmaniasis (CL) caused by various Leishmania species

Great patent on neoglycoconjugates and/or glycosides containing glycan selected from Galpα1,3Galfβ, Galpα1,6Galpα1,3Galfβ, or Galpα1,3Galfβ1,3Manpα and their use as diagnostic or prognostic biomarkers, vaccines, treating or detecting parasitic diseases, such as cutaneous leishmaniasis are disclosed.
The University of Texas at El Paso – Igor AlmeidaRosa Amelia MaldonadoAlvaro Acosta-SerranoSusana Portillo et al.

See the full patent on Espacenet